APA (7th ed.) Citation

S, K., A, W., S, P., RJ, S., JM, G., JA, C., . . . TM, J. (2024). Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas. Oncoimmunology, 13(1), 2432728. https://doi.org/10.1080/2162402X.2024.2432728

Chicago Style (17th ed.) Citation

S, Kesari, et al. "Pre-radiation Nivolumab Plus Ipilimumab in Patients with Newly Diagnosed High-grade Gliomas." Oncoimmunology 13, no. 1 (2024): 2432728. https://doi.org/10.1080/2162402X.2024.2432728.

MLA (9th ed.) Citation

S, Kesari, et al. "Pre-radiation Nivolumab Plus Ipilimumab in Patients with Newly Diagnosed High-grade Gliomas." Oncoimmunology, vol. 13, no. 1, 2024, p. 2432728, https://doi.org/10.1080/2162402X.2024.2432728.